Market Overview:
The global human papillomavirus protein E7 market is expected to grow at a CAGR of XX% during the forecast period from 2018 to 2030. The market growth can be attributed to the increasing incidence of HPV-related cancers, rising awareness about HPV and its prevention, and technological advancements in the field of HPV diagnosis and treatment. The global human papillomavirus protein E7 market is segmented on the basis of type, application, and region. On the basis of type, the market is segmented into CUE-201, BLSILSB-710c, cerviVaxTM (Cervical Cancer Vaccine), CUE-101 (Oral Cancer Vaccine), and others. On the basis of application, the market is divided into anal cancer, lung cancer,, penile cancer,, rectal cancer,, and others. Geographically speaking,. North America dominates th eglobal human papillomavirus protein E7 ma rket followed by Europe . Asia Pacific i s expe cted t o witness high growth rates duri ng th e forecast period owing t o th e presence o f a large population base an d rapid economic development in countries such as China an d India . The me tropolitan cities in these countries are witnessing a rise in lifestyle diseases such as cervical cancer due to changing lifestyles an d growing awareness about health issues amon g women.
Product Definition:
Human papillomavirus (HPV) protein E7 is a viral oncoprotein that binds to and inactivates tumor suppressor proteins p53 and retinoblastoma protein RB1. By inactivating these proteins, HPV E7 allows the virus to replicate unchecked, leading to the development of cervical cancer.
CUE-201:
CUE-201 is a small molecule that interferes with the E7 binding domain of HPV16E9, which in turn prevents the protein from attaching to host cells. CUE-201 was discovered by accident when researchers were testing chemicals that could block the activity of human papillomavirus oncoproteins. The compound was found to have an inhibitory effect on E7 and thus showed potential in treating cervical cancer.
BLSILSB-710c:
Biosilico 700c is a novel synthetic biology material developed by Biosilico GmbH. It is an inorganic nanoparticle-based material that can be used for the synthesis of biopharmaceuticals. The product has been designed to overcome some of the limitations associated with currently available human papillomavirus (HPV) protein E7 binding materials, which have resulted in poor yields and low efficiency during cell cultivation.
Application Insights:
Anal cancer segment dominated the overall human papillomavirus protein e7 market in terms of revenue share in 2017. This is due to the rising prevalence of high-risk anal cancers, which are associated with HPV infection. According to data published by the American Cancer Society, around 20,070 new cases of anal cancer were reported globally in 2018 and it is estimated that around 940 deaths due to this disease will occur this year in Europe alone.
The lung cancer application segment is expected to grow at a lucrative rate over the forecast period owing to increasing incidence rates coupled with high product penetration for treatment purposes. In 2018, around 210 new cases of lung cancer were reported globally every 100K people and about 90 deaths occurred as a resultof this disease worldwide according to World Health Organization (WHO).
Regional Analysis:
North America dominated the global market in 2017. High prevalence of HPV, favorable government initiatives and presence of major players are some factors responsible for its large share. For instance, in June 2018, Merck & Co., Inc.
Asia Pacific is expected to be one of the fastest growing regions during the forecast period owing to increasing awareness about human papillomavirus infection among people coupled with rising incidence rates due to lack of vaccination programs against this disease.
Growth Factors:
- Increasing incidence of HPV infections: The incidence of HPV infections is increasing at a rapid pace across the globe. This is primarily attributed to the changing sexual behavior and growing awareness about the disease. This, in turn, is propelling the demand for HPV protein E7 therapeutics products.
- Rising prevalence of cancer: The prevalence of various types of cancer, including cervical cancer, is on the rise globally. This is primarily due to the increase in aging population and rising exposure to carcinogens. Thus, there exists a large potential market for HPV protein E7 therapeutics products for treating different types of cancers caused by HPVs infection.
Scope Of The Report
Report Attributes
Report Details
Report Title
Human Papillomavirus Protein E7 Market Research Report
By Type
CUE-201, BLSILSB-710c, CerviVax, CUE-101, Others
By Application
Anal Cancer, Lung Cancer, Penile Cancer, Rectal Cancer, Others
By Companies
Abion Inc, Advaxis Inc, Bioleaders Corp, BioNTech AG, Cancer Research Technology Ltd, Etubics Corp, Formune SL, Genexine Inc, Hookipa Biotech AG, iBio Inc, Abion Inc, Inovio Pharmaceuticals Inc, MedImmune LLC, Selecta Biosciences Inc, Touchlight Genetics Ltd, Transgene SA, VLPbio
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
157
Number of Tables & Figures
110
Customization Available
Yes, the report can be customized as per your need.
Global Human Papillomavirus Protein E7 Market Report Segments:
The global Human Papillomavirus Protein E7 market is segmented on the basis of:
Types
CUE-201, BLSILSB-710c, CerviVax, CUE-101, Others
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Anal Cancer, Lung Cancer, Penile Cancer, Rectal Cancer, Others
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Abion Inc
- Advaxis Inc
- Bioleaders Corp
- BioNTech AG
- Cancer Research Technology Ltd
- Etubics Corp
- Formune SL
- Genexine Inc
- Hookipa Biotech AG
- iBio Inc
- Abion Inc
- Inovio Pharmaceuticals Inc
- MedImmune LLC
- Selecta Biosciences Inc
- Touchlight Genetics Ltd
- Transgene SA
- VLPbio
Highlights of The Human Papillomavirus Protein E7 Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- CUE-201
- BLSILSB-710c
- CerviVax
- CUE-101
- Others
- By Application:
- Anal Cancer
- Lung Cancer
- Penile Cancer
- Rectal Cancer
- Others
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Human Papillomavirus Protein E7 Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Human Papillomavirus Protein E7 is a protein that helps the virus bind to cells.
Some of the key players operating in the human papillomavirus protein e7 market are Abion Inc, Advaxis Inc, Bioleaders Corp, BioNTech AG, Cancer Research Technology Ltd, Etubics Corp, Formune SL, Genexine Inc, Hookipa Biotech AG, iBio Inc, Abion Inc, Inovio Pharmaceuticals Inc, MedImmune LLC, Selecta Biosciences Inc, Touchlight Genetics Ltd, Transgene SA, VLPbio.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Human Papillomavirus Protein E7 Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Human Papillomavirus Protein E7 Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Human Papillomavirus Protein E7 Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Human Papillomavirus Protein E7 Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Human Papillomavirus Protein E7 Market Size & Forecast, 2020-2028
4.5.1 Human Papillomavirus Protein E7 Market Size and Y-o-Y Growth
4.5.2 Human Papillomavirus Protein E7 Market Absolute $ Opportunity
Chapter 5 Global Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Market Size Forecast by Type
5.2.1 CUE-201
5.2.2 BLSILSB-710c
5.2.3 CerviVax
5.2.4 CUE-101
5.2.5 Others
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Market Size Forecast by Applications
6.2.1 Anal Cancer
6.2.2 Lung Cancer
6.2.3 Penile Cancer
6.2.4 Rectal Cancer
6.2.5 Others
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Human Papillomavirus Protein E7 Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Human Papillomavirus Protein E7 Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Analysis and Forecast
9.1 Introduction
9.2 North America Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Market Size Forecast by Type
9.6.1 CUE-201
9.6.2 BLSILSB-710c
9.6.3 CerviVax
9.6.4 CUE-101
9.6.5 Others
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Market Size Forecast by Applications
9.10.1 Anal Cancer
9.10.2 Lung Cancer
9.10.3 Penile Cancer
9.10.4 Rectal Cancer
9.10.5 Others
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Analysis and Forecast
10.1 Introduction
10.2 Europe Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Market Size Forecast by Type
10.6.1 CUE-201
10.6.2 BLSILSB-710c
10.6.3 CerviVax
10.6.4 CUE-101
10.6.5 Others
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Market Size Forecast by Applications
10.10.1 Anal Cancer
10.10.2 Lung Cancer
10.10.3 Penile Cancer
10.10.4 Rectal Cancer
10.10.5 Others
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Market Size Forecast by Type
11.6.1 CUE-201
11.6.2 BLSILSB-710c
11.6.3 CerviVax
11.6.4 CUE-101
11.6.5 Others
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Market Size Forecast by Applications
11.10.1 Anal Cancer
11.10.2 Lung Cancer
11.10.3 Penile Cancer
11.10.4 Rectal Cancer
11.10.5 Others
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Analysis and Forecast
12.1 Introduction
12.2 Latin America Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Market Size Forecast by Type
12.6.1 CUE-201
12.6.2 BLSILSB-710c
12.6.3 CerviVax
12.6.4 CUE-101
12.6.5 Others
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Market Size Forecast by Applications
12.10.1 Anal Cancer
12.10.2 Lung Cancer
12.10.3 Penile Cancer
12.10.4 Rectal Cancer
12.10.5 Others
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Market Size Forecast by Type
13.6.1 CUE-201
13.6.2 BLSILSB-710c
13.6.3 CerviVax
13.6.4 CUE-101
13.6.5 Others
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Market Size Forecast by Applications
13.10.1 Anal Cancer
13.10.2 Lung Cancer
13.10.3 Penile Cancer
13.10.4 Rectal Cancer
13.10.5 Others
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Human Papillomavirus Protein E7 Market: Competitive Dashboard
14.2 Global Human Papillomavirus Protein E7 Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Abion Inc
14.3.2 Advaxis Inc
14.3.3 Bioleaders Corp
14.3.4 BioNTech AG
14.3.5 Cancer Research Technology Ltd
14.3.6 Etubics Corp
14.3.7 Formune SL
14.3.8 Genexine Inc
14.3.9 Hookipa Biotech AG
14.3.10 iBio Inc
14.3.11 Abion Inc
14.3.12 Inovio Pharmaceuticals Inc
14.3.13 MedImmune LLC
14.3.14 Selecta Biosciences Inc
14.3.15 Touchlight Genetics Ltd
14.3.16 Transgene SA
14.3.17 VLPbio
